RxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk

Dow Jones

2025/07/09

0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. "It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of," say the analysts. "We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+." Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)

(END) Dow Jones Newswires

July 09, 2025 09:15 ET (13:15 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550658397"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550658397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550658397?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550658397","market":"fut","top_or_hot":-1,"title":"RxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-09 21:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXST","symbol_name":"RxSIGHT, INC.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550658397","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550658397","pubTimestamp":1752066900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXST":"RxSIGHT, INC.","BK4539":"次新股","BK4198":"医疗保健用品"},"translate_title":"即使修订后的指导重置下限，RxSight的前景仍阴云密布——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXST":0.9},"content_text":"0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 09:15 ET (13:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}